Latest Biotech News

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

Percheron Therapeutics has reported encouraging safety and efficacy signals from its HMBD-002 phase I trial, and outlined an innovative modular phase II trial design targeting multiple cancers in 2026.

Zoono Group has landed its first commercial orders from three new packaging partners, marking a key milestone in its fresh food shelf-life extension strategy. The company reports NZ$551,000 cash on hand as it navigates growth and funding options.

Amplia Therapeutics reports encouraging clinical progress for its pancreatic cancer drug narmafotinib, with a 35% confirmed response rate in the ACCENT trial and FDA support for dose optimisation. The company also uplisted to the US OTCQB market and secured a key patent extending protection to 2040.

TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.

Argent BioPharma has restructured its acquisition of AusCann assets to sharpen its clinical focus and secured a substantial A$11 million financing facility, positioning itself for growth in 2026.

Neurizon Therapeutics has locked in a $6 million cash rebate from the Australian Government’s R&D Tax Incentive, underpinning its upcoming HEALEY ALS Platform Trial with first patient dosing slated for early 2026.

ASF Group Limited closed December 2025 with $1.91 million in cash and nearly four quarters of funding runway, while progressing key investments in mining, technology, and biotech sectors.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

Patrys Limited has completed its acquisition of Reliis Pty Ltd, adding a promising injectable quetiapine program to its clinical pipeline and strengthening its board with two new directors.

Neurizon Therapeutics has successfully raised $5.88 million through a well-supported entitlement offer, reinforcing investor confidence as it prepares to advance its lead drug candidate NUZ-001 in the HEALEY ALS Platform Trial.